Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection | Zendy

Bingnan Zhang | Zendy; Richard S. Finn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection

Author(s) -

Bingnan Zhang,

Richard S. Finn

Publication year - 2016

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000367763

Subject(s) - hepatocellular carcinoma , biomarker , medicine , selection (genetic algorithm) , oncology , computer science , biology , artificial intelligence , biochemistry

Since the approval of sorafenib there have been numerous failures of new agents in Phase III studies for treatment of advanced hepatocellular carcinoma (HCC). These studies have generally ignored the molecular heterogeneity of HCC and they have not enrolled patients based on predictive markers of response. The development of molecular targeted therapeutics in HCC needs to model the approach that has been taken with great success in other solid tumors, to decrease the likelihood of failure in future studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research